Aller au contenu principal
Accès ouvert déclaré 2026 article

One-step nucleic acid amplification versus ultra-staging to detect sentinel lymph node metastasis in endometrial cancer: a randomized, multi-center, controlled trial (SENT-OSNA Trial)

0Citations signalées — pas une note de qualité
5Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

BACKGROUND: Sentinel lymph node (SLN) biopsy is the standard of care in apparent early-stage endometrial cancer. However, ultra-staging protocols have not been standardized, which may contribute to variability in the detection of SLN metastases. The one-step nucleic acid amplification (OSNA) method has been proposed as a rapid and standardized technique to diagnose SLN metastasis. PRIMARY OBJECTIVE: To compare the ability to detect SLN metastasis between OSNA and ultra-staging. STUDY HYPOTHESIS: OSNA is non-inferior to ultra-staging in detecting lymph node metastases. TRIAL DESIGN: This is a prospective, multi-center, randomized, non-inferiority trial. MAJOR INCLUSION/EXCLUSION CRITERIA: The trial includes patients with histologically confirmed endometrial cancer and apparent (pre-operative) uterine-confined tumor, who are undergoing an attempt at SLN mapping. Exclusion criteria are uterine sarcoma (except for carcinosarcomas), de-differentiated or un-differentiated histology, fertility-sparing management, neoadjuvant therapy, previous surgery to pelvic lymph nodes, and suspicious lymph nodes on pre-operative imaging. PRIMARY ENDPOINT: Incidence of SLN metastasis in the OSNA group versus the ultra-staging group. SAMPLE SIZE: Assuming a maximum allowable difference of -4% in the proportion of patients with detected lymph node metastases (node-positive proportion) to declare non-inferiority, a power of 80%, and a significance level of 2.5% (one side), a sample size of 1922 (961 per arm) is needed. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: Four years of accrual, with estimated results to be presented in 2029. TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (NCT06935305).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
One-step nucleic acid amplification versus ultra-staging to detect sentinel lymph node metastasis in endometrial cancer: a randomized, multi-center, controlled trial (SENT-OSNA Trial)
Date Crossref
01/02/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Endometrial and Cervical Cancer TreatmentsGynecological conditions and treatmentsBreast Cancer Treatment Studies

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.